Biocon and Pfizer conclude commercialisation agreement

Read Article

Our News BureauMumbai

Nobel Laureate Kurt Wuthrich inaugurating Biocon Research Centre alongside with Kiran Mazumdar-Shaw

Biocon and Pfizer announced the conclusion of their alliance to commercialise Biocon’s biosimilar versions of Insulin and Insulin analog products. The companies have agreed that due to the individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently.
Biocon and Pfizer are committed to ensuring continuity of patient care and will work together to effect a seamless transition.
“Biocon remains committed to delivering its Biosimilar Insulins portfolio to global markets in its endeavour to make a difference to diabetic patients across emerging and developed economies. Biocon will continue to work with its existing partners in several markets and will pursue a commercial strategy on its own and through new alliances in other markets,” said Kiran Mazumdar Shaw, Chairman and Managing Director, Biocon.
“Pfizer continues to be dedicated to developing a broad portfolio of biosimilars medicines, including monoclonal antibodies and recombinant proteins products, both internally and through collaborations. In addition, we will continue to be active in our own research and business development efforts for diabetes, which represents a huge unmet medical need, and we remain committed to seeking new solutions to help physicians and patients,” said Diem Nguyen, General Manager- Biosimilars, Pfizer .

Comments (0)
Add Comment